BIO vs MOH

Bio-Rad Laboratories has a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong gross margins and solid earnings surprises historically, yet faces near-term headwinds with negative profit margins, declining EPS Q/Q, and weak revenue growth. Valuation metrics suggest premium pricing with a Forward P/E of 29.22 and Price/Sales of 3.13, while insider activity is bearish and analyst recommendation remains 'buy' with a $348 target. Despite solid balance sheet strength, profitability deterioration and lack of dividend or intrinsic value clarity limit upside conviction.

Molina Healthcare exhibits a stable Piotroski F-Score of 5/9, but this is overshadowed by a severe collapse in profitability and earnings quality. The company is currently trading at $151.00, which is significantly above its growth-based intrinsic value of $62.79 and its defensive Graham Number of $126.90. A rising Medical Care Ratio (MCR) of 91.7% and negative operating margins (-1.49%) indicate that rising healthcare costs are outpacing state reimbursement rates. With a 1-year price decline of 50% and a catastrophic YoY EPS growth of -154.5%, the stock appears to be in a fundamental downtrend.